Shanghai, China
Shanghai, China

WuXi PharmaTech is a research and development services company headquartered in Shanghai, with operations in China and the United States. The company uses an open-access technology platform designed to enable efficient development of medicines for customers. WuXi acts as a contract researcher for most of the world's largest pharmaceutical, biotech and medical device companies and many smaller companies. As of April 2013, the company had more than 1,600 customers. Wikipedia.


Time filter

Source Type

Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Highly Potent Active Pharmaceutical Ingredients Market by APIs, Drugs, Manufacturing, Therapeutics and Forecast to 2020, New Research by iHealthcareAnalyst, Inc. Maryland Heights, MO, March 02, 2017 --( Browse Highly Potent Active Pharmaceutical Ingredients Market by API (Biological, Chemical), Drugs (Branded, Generic, OTC), Manufacturing (In-House, Outsourcing or Contact-Based), Therapeutic Area (Diabetes, Cardiovascular, CNS, Oncology, Musculoskeletal Drugs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/ Highly potent active pharmaceutical ingredients (HPAPIs) represent a significant change in the way pharmaceutical innovators are using small molecules to deliver new patient therapies. The shift toward highly potent APIs has not only led to a pipeline of more effective medicines that require lower doses and lead to fewer side effects, but also to new manufacturing challenges. During the last decade, the demand for HPAPIs has grown rapidly, mainly as a result of advances in clinical pharmacology and oncology research. HPAPIs drug manufacturing, storage and packaging is subject to Current Good Manufacturing Process (cGMP) regulations enforced by the U.S. FDA, EMEA and other international regulatory agencies. Contract manufacturing of HPAPI has been preferred over captive production due to high degree of competition and reduced profitability, geographical advantage and cost-effectiveness. The global highly potent active pharmaceutical ingredients (HPAPIs) market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the API (biological, chemical), drug (branded, generic, OTC), manufacturing (in-house, outsourcing or contact-based), therapeutic area (diabetes, cardiovascular, CNS, oncology, musculoskeletal drugs, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global highly potent active pharmaceutical ingredients market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global highly potent active pharmaceutical ingredients market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global highly potent active pharmaceutical ingredients (HPAPIs) market and included in this report are Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep, Sandoz International GmbH, Pfizer, Inc., Sigma-Aldrich Co. LLC, and WuXi AppTec. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, March 02, 2017 --( PR.com )-- The global potent active pharmaceutical ingredients (HPAPIs) market to reach nearly USD 18.5 Billion in 2020, at a CAGR of 6.2% from 2016 to 2020, majorly due to patent expiry of blockbuster drugs and growing trend in pharmaceutical outsourcing.Browse Highly Potent Active Pharmaceutical Ingredients Market by API (Biological, Chemical), Drugs (Branded, Generic, OTC), Manufacturing (In-House, Outsourcing or Contact-Based), Therapeutic Area (Diabetes, Cardiovascular, CNS, Oncology, Musculoskeletal Drugs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/Highly potent active pharmaceutical ingredients (HPAPIs) represent a significant change in the way pharmaceutical innovators are using small molecules to deliver new patient therapies. The shift toward highly potent APIs has not only led to a pipeline of more effective medicines that require lower doses and lead to fewer side effects, but also to new manufacturing challenges. During the last decade, the demand for HPAPIs has grown rapidly, mainly as a result of advances in clinical pharmacology and oncology research. HPAPIs drug manufacturing, storage and packaging is subject to Current Good Manufacturing Process (cGMP) regulations enforced by the U.S. FDA, EMEA and other international regulatory agencies. Contract manufacturing of HPAPI has been preferred over captive production due to high degree of competition and reduced profitability, geographical advantage and cost-effectiveness.The global highly potent active pharmaceutical ingredients (HPAPIs) market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the API (biological, chemical), drug (branded, generic, OTC), manufacturing (in-house, outsourcing or contact-based), therapeutic area (diabetes, cardiovascular, CNS, oncology, musculoskeletal drugs, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global highly potent active pharmaceutical ingredients market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global highly potent active pharmaceutical ingredients market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global highly potent active pharmaceutical ingredients (HPAPIs) market and included in this report are Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep, Sandoz International GmbH, Pfizer, Inc., Sigma-Aldrich Co. LLC, and WuXi AppTec.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


News Article | March 2, 2017
Site: www.prnewswire.co.uk

SHANGHAI and CAMBRIDGE, Mass. and REYKJAVIK, Iceland, March 2, 2017 /PRNewswire/ -- WuXi NextCODE, the contract genomics organization enabling precision medicine worldwide, today announced its presentation at the upcoming 37th Annual Cowen and Company Healthcare Conference at 10am ET on Monday, March 6th, in Boston, MA. WuXi NextCODE CEO Hannes Smarason will provide a full corporate overview and update on recent partnerships and milestones in the execution of the company's strategy to provide a fully integrated, global standard platform for using large-scale genomics data – to improve healthcare, medicine and wellness for people and populations around the world. About WuXi NextCODE WuXi NextCODE is a fully integrated global contract genomics organization. With offices in Shanghai; Kendall Square in Cambridge, Massachusetts; and Reykjavik, Iceland, we offer comprehensive services that enable population, precision medicine, diagnostics and wellness initiatives and enterprises to use the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China. WuXi NextCODE is a WuXi AppTec group company. Visit us on the web at wuxinextcode.com.


News Article | February 28, 2017
Site: www.prnewswire.com

SHANGHAI, CAMBRIDGE, Mass. and REYKJAVIK, Iceland, Feb. 28, 2017 /PRNewswire/ -- WuXi NextCODE, a WuXi AppTec group company and the contract genomics organization enabling precision medicine worldwide, today announced that the company's chief operating officer Hannes Smarason has been...


News Article | February 28, 2017
Site: www.prnewswire.co.uk

SHANGHAI, CAMBRIDGE, Mass. and REYKJAVIK, Iceland, Feb. 28, 2017 /PRNewswire/ -- WuXi NextCODE, a WuXi AppTec group company and the contract genomics organization enabling precision medicine worldwide, today announced that the company's chief operating officer Hannes Smarason has been appointed as the company's chief executive officer, and WuXi AppTec senior vice presidents John Long and Alex Fowkes have been named chief financial officer and chief operating officer, respectively. "WuXi NextCODE is executing on its vision to enable anyone to use the genome to advance health and wellness worldwide," said Dr Ge Li, founder and chairman of WuXi AppTec group and chairman of WuXi NextCODE. "It is also positioning itself as the data management platform at the heart of the genomics revolution and what may become the world's largest data ecosystem. Hannes, John and Alex have the breadth of vision and proven executive capabilities to carry out this strategy and advance the company to the next level." "This is an exciting time at WuXi NextCODE, as we work on leading projects in every facet of genomics and advance a global standard for the way genomic data is organized, mined and shared," said Mr Smarason. "John and Alex's leadership and experience in life sciences finance and operations, and in the recent independent listing of other WuXi AppTec companies, will be invaluable as we grow our business and forge our own strategic path. We are very pleased to have them join our team and offer them a warm welcome to WuXi NextCODE." Hannes Smarason co-founded NextCODE Health in 2013 as a spinout from deCODE genetics. He oversaw NextCODE's acquisition by WuXi AppTec in 2015 and its merger with the WuXi Genome Center to create WuXi NextCODE. He served as COO until January 2017 and as CEO will lead the company's overall business and corporate strategy. John Long has served as WuXi AppTec's senior vice president of finance since 2013. He was actively involved in WuXi AppTec's privatization from NYSE in 2015 and played important roles in WuXi AppTec's subsequent corporate restructuring, supporting WuXi Biologics's recent IPO filing process in Hong Kong as well as private placements in the China capital market. John has over twenty years' experience in financial management, investment and operations in the US, China and Singapore, and prior to joining WuXi AppTec served in senior roles at Willis Group, Tyco International and Lucent Technologies. In addition to finance and operations leadership, he will provide WuXi NextCODE with global expertise in governance, reporting, strategic planning, treasury and tax. John holds a bachelor's degree in economics from the University of International Business and Economics in Beijing and received his MBA from Wharton School of Business at University of Pennsylvania. Alex Fowkes has twenty years experience in the life science industry in operations, business development, strategy and legal roles. He joined WuXi AppTec in 2012 initially to lead corporate development and then most recently serving as senior vice president of commercial operations. Prior to WuXi Alex served in a variety roles for Pfizer in the US, UK, Australia and China over 14 years. About WuXi NextCODE WuXi NextCODE is a fully integrated global contract genomics organization. With offices in Shanghai; Kendall Square in Cambridge, Massachusetts; and Reykjavik, Iceland, we offer comprehensive services that enable population, precision medicine, diagnostics and wellness initiatives and enterprises to use the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China. WuXi NextCODE is a WuXi AppTec Group company. Visit us on the web at wuxinextcode.com.


This report studies Drug Discovery Outsourcing in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Request a Sample Report @ https://www.wiseguyreports.com/sample-request/963107-global-drug-discovery-outsourcing-market-research-report-2017 Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Drug Discovery Outsourcing in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Libraries Building Blocks Compound Synthesis Target Validation Split by application, this report focuses on consumption, market share and growth rate of Drug Discovery Outsourcing in each application, can be divided into Chemistry Services Biology Services Lead Optimisation Lead Identification and Screening Global Drug Discovery Outsourcing Market Research Report 2017 1 Drug Discovery Outsourcing Market Overview 1.1 Product Overview and Scope of Drug Discovery Outsourcing 1.2 Drug Discovery Outsourcing Segment by Type 1.2.1 Global Production Market Share of Drug Discovery Outsourcing by Type in 2015 1.2.2 Libraries 1.2.3 Building Blocks 1.2.4 Compound Synthesis 1.2.5 Target Validation 1.3 Drug Discovery Outsourcing Segment by Application 1.3.1 Drug Discovery Outsourcing Consumption Market Share by Application in 2015 1.3.2 Chemistry Services 1.3.3 Biology Services 1.3.4 Lead Optimisation 1.3.5 Lead Identification and Screening 1.4 Drug Discovery Outsourcing Market by Region 1.4.1 North America Status and Prospect (2012-2022) 1.4.2 Europe Status and Prospect (2012-2022) 1.4.3 China Status and Prospect (2012-2022) 1.4.4 Japan Status and Prospect (2012-2022) 1.4.5 Southeast Asia Status and Prospect (2012-2022) 1.4.6 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value) of Drug Discovery Outsourcing (2012-2022) 7 Global Drug Discovery Outsourcing Manufacturers Profiles/Analysis 7.1 Albany Mlecular Research (AMRI) 7.1.1 Company Basic Information, Manufacturing Base and Its Competitors 7.1.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.1.2.1 Libraries 7.1.2.2 Building Blocks 7.1.3 Albany Mlecular Research (AMRI) Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview 7.2 Aptuit 7.2.1 Company Basic Information, Manufacturing Base and Its Competitors 7.2.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.2.2.1 Libraries 7.2.2.2 Building Blocks 7.2.3 Aptuit Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.2.4 Main Business/Business Overview 7.3 Charles River Labratries 7.3.1 Company Basic Information, Manufacturing Base and Its Competitors 7.3.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.3.2.1 Libraries 7.3.2.2 Building Blocks 7.3.3 Charles River Labratries Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.3.4 Main Business/Business Overview 7.4 Cvance 7.4.1 Company Basic Information, Manufacturing Base and Its Competitors 7.4.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.4.2.1 Libraries 7.4.2.2 Building Blocks 7.4.3 Cvance Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.4.4 Main Business/Business Overview 7.5 Cyprtex 7.5.1 Company Basic Information, Manufacturing Base and Its Competitors 7.5.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.5.2.1 Libraries 7.5.2.2 Building Blocks 7.5.3 Cyprtex Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.5.4 Main Business/Business Overview 7.6 Dmainex 7.6.1 Company Basic Information, Manufacturing Base and Its Competitors 7.6.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.6.2.1 Libraries 7.6.2.2 Building Blocks 7.6.3 Dmainex Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.6.4 Main Business/Business Overview 7.7 Evtec 7.7.1 Company Basic Information, Manufacturing Base and Its Competitors 7.7.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.7.2.1 Libraries 7.7.2.2 Building Blocks 7.7.3 Evtec Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.7.4 Main Business/Business Overview 7.8 GenScript 7.8.1 Company Basic Information, Manufacturing Base and Its Competitors 7.8.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.8.2.1 Libraries 7.8.2.2 Building Blocks 7.8.3 GenScript Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.8.4 Main Business/Business Overview 7.9 Pharmaceutical Prduct Develpment (PPD) 7.9.1 Company Basic Information, Manufacturing Base and Its Competitors 7.9.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.9.2.1 Libraries 7.9.2.2 Building Blocks 7.9.3 Pharmaceutical Prduct Develpment (PPD) Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.9.4 Main Business/Business Overview 7.10 Quintiles 7.10.1 Company Basic Information, Manufacturing Base and Its Competitors 7.10.2 Drug Discovery Outsourcing Product Type, Application and Specification 7.10.2.1 Libraries 7.10.2.2 Building Blocks 7.10.3 Quintiles Drug Discovery Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.10.4 Main Business/Business Overview 7.11 Selcia 7.12 Viva Bitech 7.13 WIL Research Labratries 7.14 WuXi AppTec For more information, please visit https://www.wiseguyreports.com/sample-request/963107-global-drug-discovery-outsourcing-market-research-report-2017


This report studies Medical Device Analytical Testing Outsourcing in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering SGS SA Toxikon Eurofins Scientific Pace Analytical Services Intertek Group plc WuXi AppTec NORTH AMERICAN SCIENCE ASSOCIATES Envigo Charles River Laboratories International Medical Device Testing Services Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Medical Device Analytical Testing Outsourcing in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Extractable & Leachable Material Charecterization Physical Testing Bioburden Testing Sterility Testing Others Split by application, this report focuses on consumption, market share and growth rate of Medical Device Analytical Testing Outsourcing in each application, can be divided into Hospital Medical Device Manufacturers Others Global Medical Device Analytical Testing Outsourcing Market Research Report 2017 1 Medical Device Analytical Testing Outsourcing Market Overview 1.1 Product Overview and Scope of Medical Device Analytical Testing Outsourcing 1.2 Medical Device Analytical Testing Outsourcing Segment by Type 1.2.1 Global Production Market Share of Medical Device Analytical Testing Outsourcing by Type in 2015 1.2.2 Extractable & Leachable 1.2.3 Material Charecterization 1.2.4 Physical Testing 1.2.5 Bioburden Testing 1.2.6 Sterility Testing 1.2.7 Others 1.3 Medical Device Analytical Testing Outsourcing Segment by Application 1.3.1 Medical Device Analytical Testing Outsourcing Consumption Market Share by Application in 2015 1.3.2 Hospital 1.3.3 Medical Device Manufacturers 1.3.4 Others 1.4 Medical Device Analytical Testing Outsourcing Market by Region 1.4.1 North America Status and Prospect (2012-2022) 1.4.2 Europe Status and Prospect (2012-2022) 1.4.3 China Status and Prospect (2012-2022) 1.4.4 Japan Status and Prospect (2012-2022) 1.4.5 Southeast Asia Status and Prospect (2012-2022) 1.4.6 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value) of Medical Device Analytical Testing Outsourcing (2012-2022) 7 Global Medical Device Analytical Testing Outsourcing Manufacturers Profiles/Analysis 7.1 SGS SA 7.1.1 Company Basic Information, Manufacturing Base and Its Competitors 7.1.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.1.2.1 Extractable & Leachable 7.1.2.2 Material Charecterization 7.1.3 SGS SA Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview 7.2 Toxikon 7.2.1 Company Basic Information, Manufacturing Base and Its Competitors 7.2.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.2.2.1 Extractable & Leachable 7.2.2.2 Material Charecterization 7.2.3 Toxikon Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.2.4 Main Business/Business Overview 7.3 Eurofins Scientific 7.3.1 Company Basic Information, Manufacturing Base and Its Competitors 7.3.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.3.2.1 Extractable & Leachable 7.3.2.2 Material Charecterization 7.3.3 Eurofins Scientific Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.3.4 Main Business/Business Overview 7.4 Pace Analytical Services 7.4.1 Company Basic Information, Manufacturing Base and Its Competitors 7.4.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.4.2.1 Extractable & Leachable 7.4.2.2 Material Charecterization 7.4.3 Pace Analytical Services Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.4.4 Main Business/Business Overview 7.5 Intertek Group plc 7.5.1 Company Basic Information, Manufacturing Base and Its Competitors 7.5.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.5.2.1 Extractable & Leachable 7.5.2.2 Material Charecterization 7.5.3 Intertek Group plc Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.5.4 Main Business/Business Overview 7.6 WuXi AppTec 7.6.1 Company Basic Information, Manufacturing Base and Its Competitors 7.6.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.6.2.1 Extractable & Leachable 7.6.2.2 Material Charecterization 7.6.3 WuXi AppTec Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.6.4 Main Business/Business Overview 7.7 NORTH AMERICAN SCIENCE ASSOCIATES 7.7.1 Company Basic Information, Manufacturing Base and Its Competitors 7.7.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.7.2.1 Extractable & Leachable 7.7.2.2 Material Charecterization 7.7.3 NORTH AMERICAN SCIENCE ASSOCIATES Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.7.4 Main Business/Business Overview 7.8 Envigo 7.8.1 Company Basic Information, Manufacturing Base and Its Competitors 7.8.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.8.2.1 Extractable & Leachable 7.8.2.2 Material Charecterization 7.8.3 Envigo Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.8.4 Main Business/Business Overview 7.9 Charles River Laboratories International 7.9.1 Company Basic Information, Manufacturing Base and Its Competitors 7.9.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.9.2.1 Extractable & Leachable 7.9.2.2 Material Charecterization 7.9.3 Charles River Laboratories International Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.9.4 Main Business/Business Overview 7.10 Medical Device Testing Services 7.10.1 Company Basic Information, Manufacturing Base and Its Competitors 7.10.2 Medical Device Analytical Testing Outsourcing Product Type, Application and Specification 7.10.2.1 Extractable & Leachable 7.10.2.2 Material Charecterization 7.10.3 Medical Device Testing Services Medical Device Analytical Testing Outsourcing Production, Revenue, Price and Gross Margin (2015 and 2016) 7.10.4 Main Business/Business Overview For more information, please visit https://www.wiseguyreports.com/sample-request/964399-global-medical-device-analytical-testing-outsourcing-market-research-report-2017


SHANGHAI and SYDNEY, Nov 23, 2016 /PRNewswire/ -- WuXi Biologics, a WuXi AppTec group company and a leading open-access R&D capability and technology platform company dedicated to expediting global biologics development, and Prima Biomed Ltd. (Prima), an ASX (PRR) and Nasdaq (PBMD) listed company developing IMP321, a recombinant soluble LAG-3 protein and other LAG-3 related products for use in oncology, announced today that a non-binding MOU was signed to form a strategic biologics development and manufacturing partnership. Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong where rights are retained by Prima's development partner in China, Eddingpharm. WuXi Biologics will also be Prima's preferred partner to manufacture potential new products. IMP321, a first-in-class soluble LAG-3 Ig fusion protein and an APC activator boosting T cell responses for cancer chemo-immunotherapy is currently in Phase II trials in Europe. CEO of Prima BioMed, Mr. Marc Voigt said, "Securing the future supply of IMP321 is a key component of our commercial development strategy. WuXi Biologics have consistently delivered the highest quality materials for our clinical trials. This MOU further strengthens our strategic partnership." "We are honored to play a critical role to enable biotech and pharma companies to realize commercialization via WuXi's innovative biomanufacturing network based on state-of-the-art disposable manufacturing technology," said Dr. Chris Chen, CEO of WuXi Biologics, "WuXi Biologics is committed to producing the highest quality product to enable robust global supply of this potential biologics to patients worldwide." WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit http://www.wuxiapptec.com WuXi Biologics, a WuXi AppTec company, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. As a premier Contract Discovery, Development and Manufacturing Organization (CDMO), WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi's Biologics services, please visit: http://www.wuxibiologics.com. Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners. Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-biologics-and-prima-signs-mou-and-announces-strategic-development-and-manufacturing-partnership-300366442.html


Cloud management, among the digital technologies is a millstone for drug discovery platform. Since, cloud management release the load of huge data and provides easy actability to the researcher in drug discovery platform, currently is a most acceptable technology has been adopted by significant number of drug discovery platform that is called cloud-based drug discovery platform. This platform helps customers overcome many challenges by leveraging a network of web and mobile-accessible applications for instance, it provides secure and collaborative project management and the ability to share project information. Moreover, the cloud-based drug discovery platform is enough flexible to deal with any types of research and development platform, through this customization users can create their own pipeline or protocol. Currently, cloud-based drug discovery platform is getting more developed by adding more features such as publishing and sharing services. Cloud-based drug discovery platform is accessible by computers, notebook and mobile as well. Cloud-based drug discovery platform is secure and can be maintained by a third party as well. For all these benefits, the cloud-based drug discovery platform market is anticipated to grow at a significant rate in terms of value. On the basis of types of services cloud-based drug discovery platform market I segmented into Infrastructure as a Service (IaaS), Platform as a Service (PaaS) and Software as a Service (SaaS). IaaS offers data-center space, and servers, network equipment such as software for businesses and routers/switches. PaaS offers full hardware architecture and software framework. In SaaS process providers allow to access software over the net only. Geographically, global cloud-based drug discovery market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America, Western Europe are the major shareholder of cloud-based drug discovery platform market. Asia pacific market for cloud-based drug discovery platform is expected to fuel the cloud-based drug discovery platform market in the near future. Data management is a critical issue for the pharmaceutical industry.  The pharmaceutical industry is rapidly restructuring its discovery business model to completely networked and integrated research and development in order to manage the huge data. This big data concept is main growth driver for the cloud-based drug discovery platform market. Graphical representation is a dynamic and quick form of getting a result which is easy for decision making in a management level, understanding the demand of consumers, companies are offering cloud-based drug discovery platform accordingly. Cloud-based drug discover platform runts at zero lag time, that’s saves time for the users. This is another reason why pharmaceutical companies adopt cloud-based drug discover platform. However, many companies do not what to keep their confidential data in the cloud storage of the service provider which is a restraining factor for the cloud-based drug discover platform market. Moreover, due to high maintenance cost many small and medium scale pharmaceutical companies do not like to enter into Cloud-Based Drug Discovery Platform. Since, huge number of drug discovery centre are located in North America, Japan and Western Europe regions, these are the potential market for cloud-based drug discovery platform market. Many companies from this region already adopted and using cloud-based drug discovery platform, however the regions is not penetrated and have significant opportunities for cloud-based drug discovery platform market. Some of the key players operating in the cloud-based drug discovery platform market IBM Corp, Accenture PLC, BioXcel Corporation, Cloud Pharmaceuticals, Inc., WuXi AppTec (Shanghai) Co., Ltd., dassault systèmes biovia ltd.


SHANGHAI, Mar. 1, 2017 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, today announced that its Lab Testing Division(LTD)'s Bioanalytical facility in Shanghai once again passed US FDA's bioequivalence (BE) inspection with no 483 observations. The inspectors from FDA thoroughly audited WuXi's quality system during the 5-day inspection, focusing on scientific data integrity, operation infrastructure, equipment, sample storage, archival system, quality control, and quality assurance. The inspection covered two bioequivalence studies for pre-approval including method validation and sample analysis and eight other clinical bioanalytical studies from 2013 and 2016 as a general regulatory compliance inspection. "FDA has the most stringent requirement on quality and data integrity among international regulatory agencies. We are proud with the result of this audit," says Dr. Jason Liu, Senior Vice President and Chief Operating Officer of Lab Testing Division. "We will continue to maintain the highest quality standards, and provide the best-in-class R&D services for our customers worldwide." WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit http://www.wuxiapptec.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-apptec-lab-testing-divisions-bioanalytical-service-unit-passed-fda-inspection-300414865.html


News Article | March 1, 2017
Site: www.prnewswire.com

SHANGHAI, Feb. 28, 2017 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, today announced that its Lab Testing Division(LTD)'s Bioanalytical facility in Shanghai once again passed US FDA's...

Loading WuXi AppTec collaborators
Loading WuXi AppTec collaborators